Amgen Inc. (NASDAQ:AMGN) Shares Sold by Fmr LLC

FMR LLC lowered its position in Amgen Inc. (NASDAQ:AMGN - Free Report) by 13.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 3,686,212 shares of the medical research company's stock after selling 561,092 shares during the period. FMR LLC owned approximately 0.69% of Amgen worth $960,774,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Federated Hermes Inc. raised its position in Amgen by 39.6% during the fourth quarter. Federated Hermes Inc. now owns 1,371,614 shares of the medical research company's stock valued at $357,497,000 after acquiring an additional 389,099 shares in the last quarter. Ilmarinen Mutual Pension Insurance Co increased its holdings in shares of Amgen by 27.4% during the 4th quarter. Ilmarinen Mutual Pension Insurance Co now owns 72,000 shares of the medical research company's stock valued at $18,766,000 after purchasing an additional 15,500 shares in the last quarter. Nutshell Asset Management Ltd acquired a new position in shares of Amgen in the 4th quarter valued at $2,763,000. Russell Investments Group Ltd. boosted its holdings in Amgen by 4.7% during the fourth quarter. Russell Investments Group Ltd. now owns 270,560 shares of the medical research company's stock worth $70,459,000 after buying an additional 12,098 shares in the last quarter. Finally, Rahlfs Capital LLC acquired a new stake in Amgen during the fourth quarter valued at $219,000. Institutional investors and hedge funds own 76.50% of the company's stock.

Analyst Ratings Changes

Several research firms have recently issued reports on AMGN. Bank of America increased their target price on shares of Amgen from $275.00 to $294.00 and gave the stock an "underperform" rating in a research note on Wednesday, March 5th. Piper Sandler Companies reiterated an "overweight" rating and set a $310.00 target price on shares of Amgen in a research report on Thursday, January 2nd. Piper Sandler boosted their price target on shares of Amgen from $310.00 to $329.00 and gave the stock an "overweight" rating in a report on Monday, February 10th. StockNews.com raised shares of Amgen from a "buy" rating to a "strong-buy" rating in a report on Wednesday. Finally, UBS Group restated a "hold" rating on shares of Amgen in a research report on Wednesday, February 12th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $315.22.

Remove Ads

Insider Activity at Amgen

In other news, EVP David M. Reese sold 25,225 shares of the business's stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $304.44, for a total transaction of $7,679,499.00. Following the completion of the sale, the executive vice president now owns 36,922 shares in the company, valued at approximately $11,240,533.68. The trade was a 40.59 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Nancy A. Grygiel sold 1,589 shares of the stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total transaction of $483,802.83. Following the completion of the transaction, the senior vice president now directly owns 7,210 shares in the company, valued at $2,195,228.70. This trade represents a 18.06 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 69,341 shares of company stock worth $20,644,335. Company insiders own 0.69% of the company's stock.

Amgen Trading Up 1.6 %

NASDAQ:AMGN traded up $4.57 during trading hours on Friday, reaching $285.98. 3,466,932 shares of the stock were exchanged, compared to its average volume of 2,779,713. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $346.85. The business has a 50-day moving average of $304.33 and a two-hundred day moving average of $295.11. The company has a market capitalization of $153.76 billion, a price-to-earnings ratio of 37.88, a PEG ratio of 2.63 and a beta of 0.59. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its earnings results on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, beating analysts' consensus estimates of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. On average, equities analysts predict that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Friday, May 16th will be given a dividend of $2.38 per share. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.33%. The ex-dividend date is Friday, May 16th. Amgen's dividend payout ratio is currently 126.09%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.